The Ebola vaccine projects – EBOVAC1, EBOVAC2, EBOVAC3, EBODAC and EBOMAN – are a series of trials and associated projects which aim to assess a novel two-dose preventive vaccine regimen against Ebola Virus Disease (EVD). In a two-dose vaccine regimen, individuals are given a first dose to prime the immune system, and then a second dose which is intended to enhance the immune response and increase the duration of the response.
Between them the EBOVAC1, EBOVAC2 and EBOVAC3 projects are assessing – through several clinical trials conducted in phases in Europe and Africa – the safety, tolerability and immunogenicity of the vaccine regimen in response to the public health need raised by the West African Ebola epidemic of 2014-2016.
Find out more about the trials:
EBOVAC1, EBOVAC2 and EBOVAC3 are working closely with the EBODAC vaccine deployment, acceptance and compliance project, and the EBOMAN vaccine manufacture capability project.
Find out more about these projects:
EBODAC – Vaccine deployment, acceptance and compliance
EBOMAN – Vaccine manufacture capability
Ebola signs in Freetown, Sierra Leone (Credit: Dr D Watson-Jones)
The Ebola vaccine projects are part of the Innovative Medicines Initiative Ebola+ programme
